Resources
11 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/1/2021 (updated 4/5/2024)
This webinar will introduce attendees to the infrastructure, implementation, impact and adaptation of Regrounding. Our Response, a statewide effort to address stigma through collective impact underway in Maryland and being adapted in West Virginia. Structured around 5 curriculum areas, each addressing a persistent myth instrumental in upholding stigma related SUD/OUD, the content is delivered within the state at no cost by one of the 25 master presenters trained from across regions and sectors—a process being captured by the Association of State and Territorial Health Officers, who are producing a toolkit that is forthcoming.
Posted 10/14/2021 (updated 4/3/2024)
Rural Community Opioid Response Program (RCORP) grantees discussed their efforts and initiatives working with criminal justice and corrections agencies to engage individuals who are incarcerated.
Posted 8/4/2021 (updated 4/2/2024)
This session provided an opportunity to learn how to encourage faith leaders how to engage in harm reduction activities.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Treasury Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 7/20/2020 (updated 3/28/2024)
The "Navigating System Cultures across the Sequential Intercept Model (SIM)" webinar, held on June 26, 2020, and hosted by SAMHSA's GAINS Center.
Posted 2/7/2023 (updated 3/27/2024)
The Centers for Disease Control and Prevention (CDC) funded an evaluation study of post-overdose outreach programs in Massachusetts known as the PRONTO Study. This study group assessed the evidence on post-overdose outreach.
Posted 6/7/2022 (updated 3/27/2024)
The presentation outlined how the Law Enforcement Assisted Diversion/Let Everyone Advance with Dignity (LEADD) pre-arrest diversion initiative operates. It covered how public health partners can engage with law enforcement to bring about a true collaborative approach to public safety. It further discussed how the LEAD model is rooted in harm reduction.
Posted 6/7/2022 (updated 3/27/2024)
These presentations highlighted the efforts of two MAT Expansion grantees to collaborate with partners, including local community corrections entities.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.